INTRODUCTION AND OBJECTIVES:
The impact of cancerrelated inflammation pathway as a proxy of aggressiveness is well known in several cancers. In the field of renal cell carcinoma (RCC), it has been already proposed the effect of pre-treatment neutrophillymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR) and plateletlymphocyte ratio (PLR) on survival after nephrectomy. No data is available as regards the potential impact of platelet to haemoglobin ratio (PHR). We aimed to systematically test and compare the prognostic effect of all those preoperative haematological parameters on long-term survival in renal cancer patients.
METHODS: We evaluated 870 patients diagnosed with cM0 RCC and treated with partial or radical nephrectomy at a single institution. Routine laboratory measurements were performed preoperatively the day before surgery. Univariable and multivariable Cox proportional hazards regression models were used to predict cancer specific mortality (CSM) and overall mortality (OM). Covariates included age at surgery, gender, pathological T and N stage, Fuhrman grade, lymph vascular invasion, tumor size, Charlson Comorbidity Index, presence of symptoms and tumour necrosis. The likelihood of metastatic disease with small renal masses (SRM) (3cm) is controversial. We sought to determine the risk of synchronous disease at the time of renal cell carcinoma (RCC) diagnosis.
METHODS: Years 2004-2013 of the National Cancer Database (NCDB) were used to identify Renal Parenchymal Neoplasms. Patients were stratified by renal mass size in 1cm increments, starting at 1cm. Both clinical and pathologic nodal and metastatic disease were included. Additional variables including age, gender, race, tumor histology, grade, and treatment were analyzed. Logistic regression was performed to measure the association between tumor size and synchronous metastatic disease.
RESULTS: Between 2004 and 2013, there were 328,467 cases with 45,510 (13.9%) presenting with synchronous metastases. 2.9% of patients with a SRM presented with metastatic disease (nodal or distant). Among patients with a tumor 1-2cm, 2-3cm, and 3.1-4.0cm the incidence of M1 disease at diagnosis was 2.8%, 2.7%, and 5.1%, respectively. In the cohort, 22,488 (6.8%) had pathologic metastatic disease, while 37,799 (11.5%) had clinical metastatic disease (Fig 1) . Metastatic sites included lung (17.6%), bone (13.2%), liver (6.1%), and brain (3.6%). Patients with metastatic disease were more likely to be male (16.3% vs 13.6%, p<0.0001) and have a left renal mass (15.0% vs 13.4%, p<0.0001). On multivariate analysis, each 1cm size increment was associated with a corresponding increase in risk of metastatic disease. Compared to a 1.1-2.0cm mass, those with a mass >10cm were significantly more likely to have metastatic disease (OR: 19.8, p<0.0001). Increasing age (OR: 1.006), male gender (OR: 1.14), left side tumor (OR: 1.13) and poorly differentiated or anaplastic tumor grade (OR: 3.3 & 7.7 respectively) were also independently associated with increased odds of metastatic disease (all p<0.0001).
CONCLUSIONS: Renal mass size is associated with the presence of synchronous disease. In SRM, metastatic disease is present in approximately 3% of cases. This information may be used for risk stratification and patient counseling.
Cytoreductive radical nephrectomy (RN) improves survival in select patients with metastatic renal cell carcinoma (mRCC). For smaller primary tumors, however, it is unknown whether cytoreductive partial nephrectomy (PN) compromises oncologic efficacy. Our objective was first to evaluate whether the size of the primary tumor is associated with overall survival (OS) in mRCC. Second, we sought to evaluate whether PN had equivalent OS compared with RN in patients with small primary tumors.
METHODS: We queried the National Cancer Database from 2004-2013 and identified patients who underwent cytoreductive PN or RN for mRCC. Tumor size was categorized as T1a, T1b, and T2a. Rates of cytoreductive PN were analyzed over time. Descriptive statistics were used to compare patient demographics and tumor characteristics by surgical procedure (PN vs. RN) and tumor size. KaplanMeier survival analysis was used to compare OS. Multivariable Cox proportional hazards models were used to determine the effect of surgery type on OS.
RESULTS: A total of 4,464 patients met our inclusion criteria, with 94.4% undergoing a RN and 5.6% undergoing a PN. Rates of cytoreductive PN increased over time from 3.2% in 2004 to 9.4% in 2013. One-year OS was 71.3%, 69.2%, and 61.7% in patients with T1a, T1b, and T2a primary tumors, respectively (log rank test: p<0.001). In a multivariable model controlling for age, Charlson-Deyo score, histology, receipt of systemic treatment, metastasis location, and surgical procedure, T2a was a predictor of worse OS (HR 1.2, 95% CI 1.07-1.33). OS was then evaluated in patients who received a PN vs. RN in the entire cohort, as well as within each primary tumor Tstage (Figure 1) . Patients who underwent PN had significantly improved OS, which was significant for T1a and T1b tumors (p<0.01) but not for larger T2a tumors (p¼0.74). This was maintained in a Cox multivariable model. CONCLUSIONS: In patients with mRCC undergoing cytoreductive nephrectomy, primary tumor size affects OS. PN was associated with longer OS in select groups of patients with small primary tumors. Further studies are needed to establish patient selection criteria in order to optimize the surgical care of patients with mRCC. 
The influence of histology in metastatic potential is often overlooked when discussing the management options of small renal masses (SRM), with size or growth rate often serving as the triggers for the intervention. We aim to reexamine the definition of a SRM by evaluating the metastatic potential of renal masses incorporating tumor size and histology to create metastatic risk tables.
METHODS: SEER-18 registries database was queried for all cases of clear cell, papillary, and chromophobe RCC diagnosed between 2004 and 2012. There were 55,478 cases identified that included 43,783, 8,587, and 3,208 cases of clear cell, papillary and chromophobe, respectively. Tumors were stratified using 1 cm increments to determine the metastatic potential by calculating the metastatic rate at presentation for different size intervals in histologic categories.
RESULTS: For all three histologies, tumors 5 cm or less had a rate of metastatic RCC at presentation of less than 4%. The metastatic potential was highest for clear cell, followed by papillary and then chromophobe tumors. Setting a cutoff of no more than 3% for metastatic potential to be called a SRM, makes clear cell carcinoma and papillary carcinoma a SRM up to 4 cm, while the chromophobe RCC would be considered a SRM up to 7 cm.
CONCLUSIONS: While clinical staging and tumor size have been the key determinants in decision-making of patients with solid renal tumors, the histology-specific risks of metastatic potential are different for each mass. The definition of a SRM should be based on the metastatic potential and not on tumor size alone. This information could be helpful for counseling and managing patients with SRMs, as well as modifying active-surveillance protocols. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e263
